Gynaecological Cancers Risk Breast Cancer, Ovarian Cancer and Endometrial Cancer

The International Agency for Research on Cancer suggests that the burden of women's cancers including breast, ovarian, and womb will rise by 50% over the next 20 years. It is essential for us to improve early diagnosis and prevention of these cancers in our health systems. The last decade has s...

Full description

Saved in:
Bibliographic Details
Other Authors: Manchanda, Ranjit (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_78794
005 20220224
003 oapen
006 m o d
007 cr|mn|---annan
008 20220224s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-2983-7 
020 |a 9783036529837 
020 |a 9783036529820 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-2983-7  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a MBN  |2 bicssc 
100 1 |a Manchanda, Ranjit  |4 edt 
700 1 |a Manchanda, Ranjit  |4 oth 
245 1 0 |a Gynaecological Cancers Risk  |b Breast Cancer, Ovarian Cancer and Endometrial Cancer 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (338 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a The International Agency for Research on Cancer suggests that the burden of women's cancers including breast, ovarian, and womb will rise by 50% over the next 20 years. It is essential for us to improve early diagnosis and prevention of these cancers in our health systems. The last decade has seen significant strides in our ability to understand and predict a woman's risk of these cancers and offer personalized medicine approaches for risk management. There have been improvements in identifying individuals at increased risk, as well as implementing and evaluating strategies for screening and prevention. In this special collection, we bring together 16 articles from leading scientists and researchers. These capture some of the important advances observed in estimating cancer risk, providing genetic testing, offering risk management to those at increased risk, as well as screening and prevention of breast, ovarian, and womb cancers in women. This makes an important contribution to the rapidly advancing knowledge base across the area of personalized medicine and precision prevention of ovarian, endometrial, and breast cancers. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Public health & preventive medicine  |2 bicssc 
653 |a breast cancer 
653 |a galectins 
653 |a galectin-7 
653 |a galectin-8 
653 |a prognostic markers 
653 |a tumor infiltrating macrophages 
653 |a screening 
653 |a mammography 
653 |a incidence-based mortality 
653 |a population genetic testing 
653 |a ovarian cancer risk 
653 |a risk stratification 
653 |a BRCA1 
653 |a BRCA2 
653 |a RAD51C 
653 |a RAD51D 
653 |a BRIP1 
653 |a SNP 
653 |a risk modelling 
653 |a BRCA 
653 |a population testing 
653 |a cost-effectiveness 
653 |a ovarian cancer 
653 |a cancer prevention 
653 |a CA125 
653 |a HE4 
653 |a UKCTOCS 
653 |a MMT 
653 |a postmenopausal women 
653 |a rare germline variants 
653 |a susceptibility genes 
653 |a genomics 
653 |a questionnaires 
653 |a attitudes 
653 |a symptoms 
653 |a early detection 
653 |a risk assessment 
653 |a diagnostic prediction model 
653 |a triage tool 
653 |a ovarian cancer symptoms 
653 |a family history 
653 |a risk 
653 |a genes 
653 |a prevention 
653 |a dyskerin 
653 |a DKC1 
653 |a endometrial cancer 
653 |a telomerase 
653 |a proliferation 
653 |a telomeres 
653 |a obesity 
653 |a metabolomics 
653 |a liquid biopsy 
653 |a mass spectrometry 
653 |a plasma biomarkers 
653 |a artificial intelligence 
653 |a ultrasound 
653 |a TVS 
653 |a trial 
653 |a randomised controlled trial 
653 |a genomic sequencing 
653 |a tumor mutational signatures 
653 |a hereditary cancer genes 
653 |a mismatch repair 
653 |a familial cancer 
653 |a menopausal hormone therapy 
653 |a breast cancer risk 
653 |a BMI 
653 |a early BMI 
653 |a age of pregnancy 
653 |a mammographic density 
653 |a body mass index 
653 |a weight loss 
653 |a breast cancer prevention 
653 |a premenopausal 
653 |a genetic testing 
653 |a germline 
653 |a somatic 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/4889  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/78794  |7 0  |z DOAB: description of the publication